Autopsy report · NCT00814372

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“MBX-102 did not meet the target efficacy profile of HbA1c change.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 2 months before it stopped.
242 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Gilead Sciences
Sponsor type: Industry
Conditions: Type 2 Diabetes Mellitus
Interventions: MBX-102; Placebo; Actos; Metformin
Participants: 242
Sites: 26
Countries: India, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.